



SHL/SEC/2018

November 02, 2018

**Bombay Stock Exchange Limited  
Listing Department,  
1st Floor, New Trading Ring,  
Rotunda Building,  
Phiroze JeeJeeBhoy Towers, Dalal Street, Fort  
Mumbai – 400 001.**

Company Code: **537253**

Dear Sir,

**Sub. : Outcome of the 230<sup>th</sup> Board Meeting held on 02.11.2018.**

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on November 02, 2018, the meeting was started at 3:30 p.m. and concluded at 6:35 p.m.

- 1. Approved Unaudited Financial Results for the Second quarter/1<sup>st</sup> half year ended September 30, 2018 of the Financial Year 2018-19 and noted Limited Review Report on the same (Copy enclosed as Annexure-1).**
- 2. Noted the Change of Firm name of the Statutory Auditors from Jitendra K Agarwal & Associates to JKVS & Company, the letter received from Auditors Copy enclosed as Annexure-2)**
3. Noted the status on the two legal case by the Company against i) M/s Wellburt Pharmaceutical under Section 138 of NI Act for recovery of Rs. 50 lakhs at ACGM-I, Alwar. ii) M/s. Vilayil Cashews under NI Act 138 at Delhi Saket court for recovery of Rs. 69.85 lakhs
4. Noted Satisfaction of Charges with effect from 28.06.2017 by UCO Bank, New Delhi of Rs. 37.94 crores by filing form CHG-4 delay by 333 days which was condoned by Regional Director by imposing penalty of Rs. 5000/-.
5. Noted Satisfaction of Charges with effect from 29.07.2017 by UCO Bank, Alwar of Rs. 4.20 crores by filing form CHG-4 delay by 358 days which was condoned by Regional Director by imposing penalty of Rs. 2000/-.
6. Noted Satisfaction of Charges with effect from by HDFC Bank, New Delhi of Rs. 3.75 lakhs by filing form CHG-4 delay by 317 days which was condoned by Regional Director by imposing penalty of Rs. 4000/-.
7. Reconstituted Internal Complaint Committee under the provisions of POSH Act, 2013.


You are requested to take the above information in your record and oblige us.

Thanking you,

Yours sincerely,

for ~~Sunil Healthcare Limited~~

  
Santosh Kumar Sharma

Company Secretary  
FCS-6817 

Encl : As above

**CC: Calcutta Stock Exchange Limited  
7, Lyons Range  
Kolkata- 700 001.**

**Sunil Healthcare Limited**

Vijay Tower, 38E/252 - A, Shahpur Jat, Panchsheel Park Commercial Complex, New Delhi-110049

T: +91 11 49435555/00 F: +91 11 43850087 E-mail: info@sunilhealthcare.com Web.: www.sunilhealthcare.com

CIN No.: L24302DL1973PLC189662



**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2018**

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30th September 2018	30th June 2018	30th September 2017	30th September 2018	30th September 2017	31st March 2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations (Gross)	2,068.78	2,012.95	2,284.93	4,081.73	4,507.89	9,050.50
2 Other Income	12.37	33.97	19.19	46.34	50.31	200.13
3 Total Income (1+2)	2,081.15	2,046.92	2,304.12	4,128.07	4,558.20	9,250.63
4 Expenses						
a) Cost of Materials consumed	863.05	729.96	726.18	1,593.01	1,441.20	2,870.27
b) Purchase of Stock-in-trade	-	0.41	428.44	0.41	428.44	759.64
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(139.80)	10.79	(41.35)	(129.01)	(35.33)	(11.89)
d) Employees benefit expenses	331.01	321.51	294.96	652.52	581.30	1,223.87
e) Finance Costs	166.81	139.87	102.20	306.68	224.22	503.05
f) Depreciation and amortisation	138.47	144.24	117.19	282.71	232.01	478.25
g) Other Expenses	685.67	634.72	561.99	1,320.39	1,381.48	2,738.43
Total Expenses	2,045.21	1,981.50	2,189.61	4,026.71	4,253.32	8,561.62
5 Profit before tax (3-4)	35.94	65.42	114.51	101.36	304.88	689.01
6 Tax Expenses (Net)	10.13	18.04	35.19	28.17	99.54	156.62
a) Current Tax	7.65	13.73	(28.42)	21.38	33.18	87.19
b) Deferred Tax	2.48	4.31	63.61	6.79	66.36	46.47
c) Tax for Earlier Period	-	-	-	-	-	22.96
7 Net Profit for the Period (5-6)	25.81	47.38	79.32	73.19	205.34	532.39
8 Other Comprehensive Income (OCI)	0.05	0.06	(4.59)	0.11	(9.19)	(2.18)
a) Items that will not be reclassified to Profit or Loss (net of tax)	0.05	0.06	(4.59)	0.11	(9.19)	(2.18)
b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-
9 Total Comprehensive Income	25.86	47.44	74.73	73.30	196.15	530.21
10 Paid-up equity share capital (Face value per share ₹10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48
11 Other Equity	-	-	-	-	-	3,854.21
12 Earning per share of ₹ 10/- each(not annualised)						
(a) Basic (₹)	0.25	0.46	0.77	0.71	2.00	5.19
(b) Diluted (₹)	0.25	0.46	0.77	0.71	2.00	5.19

1 The business activity of the Company falls within primary business segment viz 'Capsules' and 'Marketing of food products' and disclosure under Ind AS 108 'operating segments' is given as hereunder :

**Segment wise Revenue, Results, Assets and Liabilities for the Quarter and Half year ended on 30th September 2018**

Segment wise Performance	Quarter Ended Standalone			Half Year Ended Standalone		Year Ended
	30th September 2018	30th June 2018	30th September 2017	30th September 2018	30th September 2017	31st March 2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Segment Revenue						
Capsules	2,068.78	2,012.95	1,861.15	4,081.73	4,084.11	8,308.71
Marketing of Food Products	-	-	423.78	-	423.78	741.79
Total Income From Operations	2,068.78	2,012.95	2,284.93	4,081.73	4,507.89	9,050.50
2 Segment Results						
Capsules	200.78	207.73	225.09	402.89	564.77	1,323.61
Marketing of Food Products	14.69	20.87	(5.06)	35.56	(14.17)	(49.86)
Profit/(Loss) Before Finance Cost and Tax	215.47	228.60	220.03	438.45	550.60	1,273.75
Less: Finance Cost	166.81	139.87	102.20	306.68	224.22	503.05
Less: Un-allocable Expenses / (Income)(Net)	12.72	23.31	3.32	30.41	21.50	81.69
Profit/(Loss) Before Tax	35.94	65.42	114.51	101.36	304.88	689.01
3 Segment Assets						
Capsules	13,235.96	13,175.61	11,556.44	13,235.96	11,556.44	12,934.14
Marketing of Food Products	597.37	736.46	979.53	597.37	979.53	770.41
Unallocated Assets	239.11	445.85	456.00	239.11	456.00	554.29
Total	14,072.44	14,357.92	12,991.97	14,072.44	12,991.97	14,258.84
4 Segment Liabilities						
Capsules	2,842.93	2,513.05	2,106.28	2,842.93	2,106.28	2,276.72
Marketing of Food Products	249.09	350.49	607.71	249.09	607.71	386.79
Unallocated Liabilities	6,027.42	6,567.26	5,730.11	6,027.42	5,730.11	6,715.64
Total	9,119.44	9,430.80	8,444.10	9,119.44	8,444.10	9,379.15



2/5


## Statement of Assets and Liabilities (Standalone)

	As at 30th September 2018	As at 31st March 2018
	Unaudited	Audited
<b>A ASSETS</b>		
<b>A ASSETS</b>		
<b>1 Non Current Assets</b>		
(a) Fixed Assets		
(i) Tangible Assets( Property, Plant and Equipment)	6,971.18	7,064.19
(ii) Capital Work-In-Progress	1.31	18.53
(iii) Other Intangible Assets	25.00	27.96
(b) Financial Assets		
(i) Investment	23.01	23.01
(ii) Loans	165.81	177.10
(c) Other non-current Assets	5.77	7.79
<b>2 Current Assets</b>		
(a) Inventories	1,066.50	974.27
(b) Financial Assets		
(i) Trade Receivables	4,746.26	4,797.57
(ii) Cash and Cash Equivalents	202.24	65.18
(iii) Other Bank Balances	117.31	401.88
(iv) Loans	27.61	-
(v) Other Financial Assets	10.77	43.65
(c) Current Tax Assets	28.76	8.66
(d) Other Current Assets	680.91	649.05
<b>TOTAL ASSETS</b>	<b>14,072.44</b>	<b>14,258.84</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>1 Equity</b>		
(a) Equity Share Capital	1,025.48	1,025.48
(b) Other Equity	3,927.52	3,854.21
<b>2 Non Current Liabilities</b>		
(a) Financial Liabilities- Borrowings	1,145.11	1,829.72
(b) Provisions	231.98	200.59
(c) Deferred Tax Liabilities (Net)	611.10	604.27
<b>3 Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	3,501.97	3,858.41
(ii) Trade Payables	2,264.90	1,788.09
(iii) Other Financial Liabilities	855.85	556.28
(b) Other Current Liabilities	460.30	489.89
(c) Provisions	48.23	48.23
(d) Current tax liabilities(Net)	-	3.67
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>14,072.44</b>	<b>14,258.84</b>

- 2 After applicability of Goods and Service Tax (GST) w.e.f. July 1, 2017, sales are required to be disclosed net of GST. Accordingly, the figures of revenue from operations for the half year ended September 30, 2018 not comparable with the previous corresponding half year ended September 30, 2017.
- 3 The Company has preliminary assessed impact of Ind AS 115 "Revenue from Contracts with Customers" effective from 1st April 2018 and found no material impact. Final adjustment, if any, shall be made after completion of final assessment.
- 4 The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to conform current period classifications.
- 5 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 2, 2018 and the statutory auditor of company has carried out of the limited review of the same.

Place: NEW DELHI  
Date: 02.11.2018

For & On Behalf of the Board  
*Anil Khaitan*  
Anil Khaitan  
Chairman Cum Managing Director  
DIN 00759951



3/5

**JKVS & Co.**  
**Chartered Accountants**

**Review Report on Quarterly and Year to date Financial Results Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation 2015**

**To the Board of Directors of Sunil Healthcare Limited**

We have reviewed the accompanying statement of unaudited financial results ("Statement") of Sunil Healthcare Ltd. ("the Company") for the quarter and half year ended September 30, 2018, which are prepared by the Management in accordance with the Indian Accounting Standards ('Ind AS') as per Section 133 of the Companies Act, 2013 read with the Companies (Indian Accounting Standards) Rules, 2015. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For JKVS & Co.  
(Formerly known as Jitendra K Agarwal & Associates)  
Chartered Accountants  
Firm Registration No. 318086E



*Kuldeep Maloo*

Kuldeep Maloo  
Partner  
Membership No. 515708

Place: New Delhi  
Date: November 02, 2018

*JK*

**JKVS & Co.**  
**Chartered Accountants**

Date: 1<sup>st</sup> November'2018

Sunil Healthcare Ltd.  
38E/252-A, Vijay Tower,  
Shahpurjat  
New Delhi - 110049

Dear Sir,


Attn: Mr. Santosh Sharma – Company Secretary

We wish to inform you that our firm's name has been change to JKVS & Co. as approved by The Institute of Chartered Accountants of India (ICAI). Please note there is no change in the constitution of the firm and registration number allotted by ICAI You are requested to take on record the same.

Assuring our best services as and when required.

Thanking you

JKVS & Co.  
(Formerly known as Jitendra K Agarwal & Associates)  
Chartered Accountants

  
Kuldeep Maloo  
Partner

5/5